Unum Therapeutics, Inc.
SEC CIK 1622229 · UNUM · last insider filing 2026-06-11
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Morris Arlene | Director | filed 2019 - 2026 |
| Ferrante Karen Jean | Director | filed 2018 - 2026 |
| Harwin Peter Evan | Director | filed 2020 - 2026 |
| Ros Matthew | Director | filed 2019 - 2026 |
| Shegog Todd | Director | filed 2021 - 2026 |
| Cain Christopher W. | Director | filed 2020 - 2026 |
| Robbins Andrews R | Director · President and CEO | filed 2020 - 2026 |
| Fairmount Funds Management LLC | Director | filed 2020 - 2026 |
| Booth Bruce | Director | filed 2018 - 2020 |
| Aldag Jorn | Director | filed 2018 - 2020 |
| Perez Robert J | Director | filed 2018 - 2019 |
| Ratcliffe Liam | Director | filed 2018 - 2019 |
| Wilson Charles | Director · Chief Executive Officer | filed 2018 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Green John L. | See Remarks | filed 2019 - 2025 |
| Kearns Evan | Chief Legal Officer | filed 2021 - 2025 |
| Sachs Jessica | Chief Medical Officer | filed 2019 - 2025 |
| Robinson John Edward | Chief Scientific Officer | filed 2021 - 2025 |
| Pinnow Cole | Chief Commercial Officer | filed 2024 - 2025 |
| Ettenberg Seth | Chief Scientific Officer | filed 2018 - 2020 |
| Hodge Geoffrey | Chief Technical Officer | filed 2018 - 2020 |
| Osborne Matthew Scott | Chief Financial Officer | filed 2019 - 2020 |
| Vasconcelles Michael | Chief Medical Officer | filed 2018 - 2019 |
| Stamoulis Christiana | President & C.F.O. | filed 2018 - 2018 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.